Need to find a common ground with Moderna and Johnson & Johnson for initiating vaccine supply : V K Paul

Discussions are still going on with Moderna and Johnson & Johnson vaccine manufacturers to start their vaccine supplies, though the government has given Emergency Use Authorisation (EUA) for these COVID-19 vaccines, said Dr Vinod K Paul, member of NITI Aayog.

It may be noted that the foreign vaccine manufacturers including Pfizer and Moderna have been seeking indemnity against any legal issues if the vaccine may create any serious adverse reactions.

Apprising the same in a weekly press briefing on COVID-19 developments in the country, Paul informed that the option for using EUA is open for both the companies. “With regard to their import or deployment from the production of Johnson and Johnson in the country, we have been informing you that there are issues around which we still have to find a common ground with respective vaccine manufacturers and we are working in that direction.”

Commenting on the vaccine administration in children, Paul said that Zydus Cadila’s vaccine has been approved for potential use in children.

“We have information on the stock pile and our scientific bodies are discussing how and when and where to. Covaxin trial is very close to completion of trials for children. Once we have results, that vaccine will be potentially available. Biological E has also been granted permission to complete the trial,” he said.

Health Secretary, Rajesh Bhushan, Ministry of Health and Family Welfare, said, “We are still witnessing the second surge. It is not over. Public health response should be on the basis that the second surge is not over though the cases are coming down.”

He urged the public to be careful while celebrating the upcoming festivals in the wake of the pandemic.

  • Related Posts

    Maharashtra FDA permanently cancels Pune-based pharma firm’s license over six contaminated medicines, GMP lapses

    The inspection revealed incomplete manufacturing records, poor hygiene, inadequate quality-control systems and the omission of ingredients specified in approved Ayurvedic formulations. The Maharashtra Food and Drug Administration (FDA) on Thursday…

    Amneal Pharma completes acquisition of Kashiv BioSciences

    Amneal Pharmaceuticals, Inc. announced the completion of its acquisition of Kashiv BioSciences, LLC, creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialization. The…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Maharashtra FDA permanently cancels Pune-based pharma firm’s license over six contaminated medicines, GMP lapses

    Maharashtra FDA permanently cancels Pune-based pharma firm’s license over six contaminated medicines, GMP lapses

    Amneal Pharma completes acquisition of Kashiv BioSciences

    Amneal Pharma completes acquisition of Kashiv BioSciences

    Delhi High Court Directs Meesho to Remove Alleged Counterfeit Sun Pharma Sunscreen Listings

    Delhi High Court Directs Meesho to Remove Alleged Counterfeit Sun Pharma Sunscreen Listings

    IIT Guwahati Develops ‘E-Eye’ for Rapid Detection of Cancer-Causing Heavy Metals and Other Toxicants

    IIT Guwahati Develops ‘E-Eye’ for Rapid Detection of Cancer-Causing Heavy Metals and Other Toxicants

    AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

    AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

    NHS backs delayed‑release treatment for cystinosis

    NHS backs delayed‑release treatment for cystinosis